Top 5 Epilepsy treatments startups in USA

Oct 12, 2024 | By Jason Kwon

1
Funding: $573.1M
Praxis is a clinical-stage genetic neuroscience company that develops high-impact therapies for patients and families affected by complex and debilitating brain disorders
2
Funding: $307.3M
NeuroPace develops and markets implantable devices for the treatment of neurological disorders.
3
Funding: $260M
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
4
Funding: $23.4M
Zeto is transforming EEG for hospitals with a wireless, zero-prep, dry electrode headset backed by a state-of-the-art cloud platform
5
Funding: $18.4M
NeuroSigma is a life sciences company focused on bioelectronics products and commercialization of its unique Trigeminal Nerve Stimulation (TNS) technology, and has a growing pipeline of treatments targeting epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), Lennox Gastaut syndrome (LGS) and traumatic brain injury (TBI).
Editor: Jason Kwon
Jason Kwon is a senior editor for MedicalStartups. He has previously covered the pharmaceutical and medical research industries for FDAnews and worked as a head of marketing for medical startup Sonic Therapeutics. Before that, he co-founded a startup consulting business for emerging entrepreneurial hubs in Asia. Jason graduated from St. Bonaventure University’s journalism school. In his free time, Jason enjoys yoga, watching movie trailers, traveling to places where he can't get cell service. You can contact Jason at jaskwon(at)medicalstartups(dot)com